Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Sellas Life Sciences Stock Triples After Cancer Vaccine Data

Sellas Life Sciences Group Inc. surged after the drug developer reported positive late-stage trial results for an experimental cancer vaccine to treat an aggressive form of blood cancer.

We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.

Read the original at bloomberg.com →

More in Finance & Markets

More from Tuesday 17 November →